| Literature DB >> 32041140 |
Mahshid Moballegh Nasery1,2,3, Banafshe Abadi1, Delaram Poormoghadam4, Ali Zarrabi5, Peyman Keyhanvar6,7, Hashem Khanbabaei8, Milad Ashrafizadeh9, Reza Mohammadinejad10, Shima Tavakol11, Gautam Sethi12.
Abstract
Todays, nano-pharmaceutics is emerging as an important field of science to develop and improve efficacy of different drugs. Although nutraceuticals are currently being utilized in the prevention and treatment of various chronic diseases such as cancers, a number of them have displayed issues associated with their solubility, bioavailability, and bio-degradability. In the present review, we focus on curcumin, an important and widely used polyphenol, with diverse pharmacological activities such as anti-inflammatory, anti-carcinogenic, anti-viral, etc. Notwithstanding, it also exhibits poor solubility and bioavailability that may compromise its clinical application to a great extent. Therefore, the manipulation and encapsulation of curcumin into a nanocarrier formulation can overcome these major drawbacks and potentially may lead to a far superior therapeutic efficacy. Among different types of nanocarriers, biological and biopolymer carriers have attracted a significant attention due to their pleiotropic features. Thus, in the present review, the potential protective and therapeutic applications of curcumin, as well as different types of bio-nanocarriers, which can be used to deliver curcumin effectively to the different target sites will be discussed.Entities:
Keywords: biopolymer; cancer; curcumin; exosomes.; nanocarriers
Year: 2020 PMID: 32041140 PMCID: PMC7037405 DOI: 10.3390/molecules25030689
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
A list of different curcumin nanocarriers with their characteristics and applications under in vitro and in vivo settings.
| Polymer | Size | Zeta Potential | LC or EE | Cell Line/Animal Model | Advantages | Refs. |
|---|---|---|---|---|---|---|
| BSA@CUR NPs | 92.59 ± 16.75 nm | −9.19 mV | 18.3% | MCF-7 cells | Increased therapeutic efficacy | [ |
| Curcumin in BSA-dextran NP | 115 nm | 2.8% | Caco-2 cells | Better stability | [ | |
| Curcumin cross-linked HSA NPs | 125 nm | −12.36 ± 0.73 to −10.88 ± 0.6 mV | was dependent on the particle size | A549 cells | Improved cellular uptake | [ |
| Curcumin-loaded zein NPs | 66 nm | +17.1 mV | 7.3 ± 0.1% | GIT model | May be useful for application in functional foods or beverages | [ |
| Curcumin-zein/rhamnolipid complex | 77.29 nm | −31 mV To +3 mV | EE: 98.05% | In vitro simulated gastrointestinal tract | Protect hydrophobic bioactive compounds | [ |
| Pectin-coated CZ NPs | 250 nm to 600 nm | −45 to −50 mV | 5% | Simulated gastrointestinal digestive condition | Enhanced antioxidant activity in an aqueous environment | [ |
| Curcumin-loaded zein NPs with (SC) and (SA) | 190 nm | 17 mV to 19.8 mV | EE: 36.10% to 76.06% | Improving the water solubility | [ | |
| Curcumin-loaded silk fibroin NPs | 155 nm to 170 nm | −45 mV | EE: 50% | Kelly Cells | Higher efficacy in cytotoxicity | [ |
| Curcumin plus SFNs | 71 ± 10 nm | 1.50 ± 0.11 to 11.40 ± 0.76 | In vitro model of osteoarthritis | Exhibited a synergistic antioxidant effect | [ | |
| CUR-loaded silk NPs | 229 nm to 2286 nm | −17.8 nm to −18.9 mV | 22 to 41% | Rats | Longer plasma circulation time | [ |
| CUR Loaded RBA−CS NPs | 778 nm | Negative | EE: 93.56% | Caco-2 cells | A great potential application for hydrophobic active agent delivery | [ |
| Zein-HA NPs | 186.4 nm | –35.2 to −28.7 mV | 3.66% | Simulate gastrointestinal digestion | Better stability of anti-light degradation, and control release | [ |
| SSPS NPs | 200 nm to 300 nm | EE: 90% | HCT116 and MCF-7 cells | Improved activity | [ | |
| Cur-ACRU/CS NPs | 200 nm to 450 nm | +15 mV | 5.4% | Caco-2 cells | Improved permeability efficiency of free curcumin | [ |
| Cur-Chitosan NPs | 167 nm to 251 nm | + 18.1 to + 20.2 mV | EE: 80% | HaCaT cells | Superior drug release | [ |
| CDG-CANPs | 215 nm | −24.1 mV | 27% | Caco-2 cells | Improvement of physicochemical stabilities, digestibility, bioaccessibility and cellular uptake | [ |
| CUR-AlgNP | 100-600 nm | −36.0± 0.4 | EE: 68.3% | HeLa and H9c2 | Kills the cancer cell lines at lower concentrations | [ |
| Cur-CS/Alg NPs | 199 nm to 1120 nm | −30.8 mV to −10.8 mV | 0% to 27.4% | HaCaT cells | Improved the cellular uptake of curcumin | [ |
| Starch NPs | < 250 nm | −30 mV | EE: 80% | Simulated gastric and intestinal fluids | Higher encapsulation efficiency | [ |
| OSA starch loaded nano curcumin | 10 nm to 50 nm | HeLa cells | Anti-cancer potential | [ | ||
| Curcumin-load film | 159 ± 31 nm in length and 2 nm in width. | Rat | Improved the regeneration of hair follicles | [ | ||
| Cur- NLCs | 500 nm | EE~58.8 ± 3.5 | Mouse | Reducing the pro-inflammatory cytokine levels in the skin | [ | |
| ANC NPs | ≤150 nm | -31.2 ± 3.66 mV | EE > 90% | L929 and MCF-7 cells | Inhibit microbial growth | [ |
| WPI-Lac/EGCG NPs | 110 nm | 27 mV | Better protective effect on the breakdown of curcumin in Pickering emulsions | [ | ||
| CUR-Loaded Gel-mPEG Nanogels | 147 ± 5.2 nm | −12.8 ± 0.6 | 7.9 ± 0.2%, | HeLa cells | Improved solubility | [ |
| Curcumin-loaded BSA NPs | 150 nm | Negative | EE: 45% | Murine melanoma model | Increase in survival rate associated with a reduction in tumor size | [ |
| Curcumin loading EWP | 59.25 nm to 431.3 nm | >+30 mV | 11.2 mg/g | Protect the antioxidant activity of encapsulated curcumin | [ | |
| Curcumin-PECs | 264.0 ± 3.1 nm | EE: 53% | HCT116 cells | Induced cell cycle arrest | [ |
Targeted curcumin delivery using biopolymers-based nanoparticles.
| Polymer | The Route of Targeting | Size | Zeta Potential | LC or EE | Cell Line/Animal Model | Advantages | Refs. |
|---|---|---|---|---|---|---|---|
| F-CUR-HSANPs | Folate | 165.6 ± 15.7 nm | −27.3 ± 4.2 mV | EE:88.7% ± 4.8% | Murine colon cancer model | Maintained sustained release, and a faster release of CM compare to the unconjugated NPs | [ |
| Apt-HSA/CCM NP | Aptamer to target HER-2 positive cells | 281.1 nm | −33.3 ± 2.5mV | 3.4% | SK-BR3 cells | Higher toxicity | [ |
| Gal-BSA-Cur NPs | Galactosylation to target asialoglycoprotein receptor (ASGPR) overexpressed on hepatocellular carcinoma (HCC) cells | 116.24 nm | −14.12 ± 1.81 | EE:55.47% ± 0.45% | HCC cell line | Enhanced the internalization ability of drug compared with BSA NPs-loaded curcumin | [ |
| Zein and HA for the co-delivery of curcumin and quercetagetin | HA | 231 nm | −30.5 mV | 2.5% | simulated gastrointestinal tract conditions | Improve oral bioavailability | [ |
| Curcumin loaded magnetic silk fibroin core–shell NPs | Magnetic NP | 30 nm to 250 nm | LC: 8.4% | MDA-MB-231 cells | Enhanced growth inhibition | [ | |
| Bi2S3@BSA-FA-CUR | Folic acid | 170.9 nm | −23.2 mV | LC:10 ± 1.51% | The mouse breast carcinoma cell line, Murine breast cancer model | Enhanced the efficacy of chemoradiation therapy | [ |
| magnetic alginate/chitosan layer-by-layer nanoparticles (MACPs) | Fe3O4 NPs | 172 nm to 199 nm | EE: 49.2% | MDA-MB-231 breast cancer cells, HDF cells | The sustained release profiles, enhanced uptake efficiency and cytotoxicity to cancer cells | [ | |
| folic acid tagged aminated starch/ZnO coated iron oxide nanoparticles as targeted curcumin delivery system | Fe3O4 NPs | 31.2 ± 2 | 42.9 ± 0.03 | EE: 76.8 ± 0.04% | HepG2 and MCF7 cell lines | Enhanced the uptake by HepG2 cells | [ |
| Cur loaded MnFe2O4–CMC | Fe2O4 NPs | 35 nm | MCF7 and HeLa cells | Enhanced the therapeutic efficacy | [ |